Canada markets open in 3 hours 58 minutes
  • S&P/TSX

    19,654.92
    +135.49 (+0.69%)
     
  • S&P 500

    4,002.87
    +51.30 (+1.30%)
     
  • DOW

    32,560.60
    +316.02 (+0.98%)
     
  • CAD/USD

    0.7301
    +0.0006 (+0.08%)
     
  • CRUDE OIL

    69.26
    -0.41 (-0.59%)
     
  • Bitcoin CAD

    38,544.68
    +569.52 (+1.50%)
     
  • CMC Crypto 200

    613.13
    +8.09 (+1.34%)
     
  • GOLD FUTURES

    1,947.00
    +5.90 (+0.30%)
     
  • RUSSELL 2000

    1,777.74
    +32.75 (+1.88%)
     
  • 10-Yr Bond

    3.6060
    0.0000 (0.00%)
     
  • NASDAQ futures

    12,833.00
    -34.25 (-0.27%)
     
  • VOLATILITY

    21.81
    -2.34 (-9.69%)
     
  • FTSE

    7,521.41
    -14.81 (-0.20%)
     
  • NIKKEI 225

    27,466.61
    +520.94 (+1.93%)
     
  • CAD/EUR

    0.6761
    -0.0009 (-0.13%)
     

COVID shot drives CanSinoBIO's first six-month profit since at least 2019

FILE PHOTO: China's vaccine specialist CanSino Biologics Inc in Tianjin

BEIJING (Reuters) - Chinese vaccine maker CanSino Biologics Inc (CanSinoBIO) said on Friday it had returned to operating profit of 802.3 million yuan ($123.79 million) in the first six months of 2021, driven by use of its COVID-19 shot. That compared with 123.0 million yuan of operating loss in the same period a year ago, CanSinoBIO said in a filing in the Hong Kong stock exchange. It marks the first six-month profit since at least 2019. The firm is yet to achieve full-year profits since it went public in 2018 in Hong Kong.

It reported 937.1 million yuan profit and total comprehensive income for the first six months of 2021. Its single-dose COVID-19 shot, named Ad5-nCoV, has been approved for use in countries including China, Mexico, Pakistan and Chile. The vaccine approvals were one of the major drivers for the sixth-month profit, CanSinoBIO said.

($1 = 6.4813 Chinese yuan renminbi)

(Reporting by Roxanne Liu and Ryan Woo; Editing by Catherine Evans)